CorMedix Inc. (CRMD)
NASDAQ: CRMD · Real-Time Price · USD
8.57
-0.30 (-3.38%)
At close: Dec 20, 2024, 4:00 PM
8.75
+0.18 (2.10%)
After-hours: Dec 20, 2024, 6:28 PM EST
Company Description
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States.
Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007.
CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
CorMedix Inc.
| Country | United States |
| Founded | 2006 |
| IPO Date | Mar 25, 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 83 |
| CEO | Joseph Todisco |
Contact Details
Address: 300 Connell Drive, Suite 4200 Berkeley Heights, New Jersey 07922 United States | |
| Phone | 908 517 9500 |
| Website | cormedix.com |
Stock Details
| Ticker Symbol | CRMD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001410098 |
| CUSIP Number | 21900C308 |
| ISIN Number | US21900C3088 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joseph Todisco MBA | Chief Executive Officer and Director |
| Dr. Matthew T. David M.D. | Executive Vice President and Chief Financial Officer |
| Erin Mistry | Executive Vice President and Chief Commercial Officer |
| Elizabeth Masson-Hurlburt B.A. | Executive Vice President and Chief Clinical Strategy and Operations Officer |
| Kaufman Beth Zelnick Esq. | Executive Vice President, Chief Legal Officer and Corporate Secretary |
| Donna Ucci | Senior Vice President and Head of Global Quality |
| Dr. Tushar Mukherjee | Senior Vice President and Head of Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 25, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 144 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 30, 2024 | 10-Q | Quarterly Report |
| Oct 30, 2024 | 8-K | Current Report |
| Oct 8, 2024 | DEF 14A | Other definitive proxy statements |
| Aug 14, 2024 | 10-Q | Quarterly Report |
| Aug 14, 2024 | 8-K | Current Report |
| May 22, 2024 | EFFECT | Notice of Effectiveness |
| May 15, 2024 | UPLOAD | Filing |